0001562180-24-001395.txt : 20240216
0001562180-24-001395.hdr.sgml : 20240216
20240216182844
ACCESSION NUMBER: 0001562180-24-001395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mills Kenneth T.
CENTRAL INDEX KEY: 0001652824
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 24650003
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-14
false
0001590877
REGENXBIO Inc.
RGNX
0001652824
Mills Kenneth T.
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
true
true
false
false
President and CEO
true
Common Stock
2024-02-14
4
M
false
15000.00
3.76
A
423035.00
D
Common Stock
2024-02-14
4
S
false
4652.00
16.4716
D
418383.00
D
Common Stock
2024-02-14
4
S
false
10348.00
16.8847
D
408035.00
D
Stock Options (Right to Buy)
3.76
2024-02-14
4
M
false
15000.00
0.00
D
2025-05-19
Common Stock
15000.00
126354.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $15.78 to $16.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide
upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $16.78 to $17.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested
in equal monthly installments over the 36 months thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2024-02-16